07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Araclon sales and marketing update

Araclon launched its ABtest 40 and ABtest 42 blood-based tests to diagnose Alzheimer's disease (AD) for research use only. The tests measure free and bound beta amyloid in blood. Araclon Biotech S.L. , Zaragoza, Spain...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Clinical News

Abtest: Extension study started

Araclon began the single-blind, international extension portion of a pilot study evaluating Abtest for 2 years in about 400 healthy volunteers and patients with cognitive impairment. Araclon Biotech S.L. , Zaragoza, Spain   Product: Abtest...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

Abtest: Pilot trial data

A pilot study of blood samples from 40 subjects showed that Abtest could differentiate between healthy controls and subjects with amnesic mild cognitive impairment (MCI) with >75% specificity, >85% sensitivity and >80% accuracy. Data were...